La Jolla, CA – According to filings with the U.S. Securities and Exchange Commission, Boundless Bio is raising $105,585,007.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Zachary Hornby played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Boundless Bio

We at Boundless Bio are pioneers in understanding and treating the most intractable cancers. We have charted a new spatial map of the cancer genome within cancer cells and are harnessing our scientific founders’ discoveries about extrachromosomal DNA, or ecDNA, to drive a revolution in cancer therapeutics. Developing an entirely new class of therapeutics requires boldness, commitment, creativity, and an entrepreneurial spirit. We are building a team of pioneers committed to driving a scientific revolution in how the most difficult-to-treat cancers are understood and treated. Above all else, our commitment is to the patients we strive to help. We aim to create the first therapeutics capable of dismantling one of cancer’s trickiest evasive mechanisms  ecDNA.

To learn more about Boundless Bio, visit http://boundlessbio.com/

Contact:
Zachary Hornby, President and Chief Executive Officer
858-766-9912
zhornby@boundlessbio.com
https://www.linkedin.com/in/zacharyhornby/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved